相似文献
1
Intratumoral and intertumoral heterogeneity drives EGFR treatment considerations.
J Thorac Dis. 2022 May;14(5):1299-1301. doi: 10.21037/jtd-22-312.
2
Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer.
Pathol Res Pract. 2020 Nov;216(11):153229. doi: 10.1016/j.prp.2020.153229. Epub 2020 Sep 21.
3
The Intratumoral Heterogeneity Reflects the Intertumoral Subtypes of Glioblastoma Multiforme: A Regional Immunohistochemistry Analysis.
Front Oncol. 2020 Apr 24;10:494. doi: 10.3389/fonc.2020.00494. eCollection 2020.
5
Immunohistochemically Characterized Intratumoral Heterogeneity Is a Prognostic Marker in Human Glioblastoma.
Cancers (Basel). 2020 Oct 13;12(10):2964. doi: 10.3390/cancers12102964.
6
A Pilot Study of Baseline Spatial Genomic Heterogeneity in Primary Gastric Cancers Using Multi-Region Endoscopic Sampling.
Front Oncol. 2020 Feb 25;10:225. doi: 10.3389/fonc.2020.00225. eCollection 2020.
7
Intrapatient homogeneity of BRAFV600E expression in melanoma.
Am J Surg Pathol. 2014 Mar;38(3):377-82. doi: 10.1097/PAS.0000000000000136.
8
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
J Clin Oncol. 2015 Nov 10;33(32):3701-9. doi: 10.1200/JCO.2014.58.8293. Epub 2015 Sep 28.
9
Intertumoral and intratumoral heterogeneity as a barrier for effective treatment of medulloblastoma.
Neurosurgery. 2013 Aug;60 Suppl 1:57-63. doi: 10.1227/01.neu.0000430318.01821.6f.
10
The Local Recurrence of Breast Cancer with Squamous Metaplasia and Obvious Histological Heterogeneity.
Anticancer Res. 2017 Sep;37(9):5249-5254. doi: 10.21873/anticanres.11949.
引用本文的文献
1
A Comprehensive Review of Epidermal Growth Factor Receptor Mutation Abundance in Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.
Oncol Res Treat. 2024;47(12):602-609. doi: 10.1159/000541520. Epub 2024 Oct 1.
本文引用的文献
1
The role of salvage surgery in the treatment of a gefitinib-resistant non-small cell lung cancer patient: a case report.
J Thorac Dis. 2021 Jul;13(7):4554-4559. doi: 10.21037/jtd-21-171.
2
Non-invasive lung cancer diagnosis and prognosis based on multi-analyte liquid biopsy.
Mol Cancer. 2021 Jan 29;20(1):23. doi: 10.1186/s12943-021-01323-9.
3
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
JAMA Oncol. 2021 Mar 1;7(3):386-394. doi: 10.1001/jamaoncol.2020.6758.
4
A new method for accurately localizing and resecting pulmonary nodules.
J Thorac Dis. 2020 Sep;12(9):4973-4984. doi: 10.21037/jtd-20-2089.
5
First-line treatment selection with organoids of an m + m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up.
J Thorac Dis. 2020 Jul;12(7):3764-3773. doi: 10.21037/jtd-20-1882.
6
Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q.
J Thorac Dis. 2020 May;12(5):2771-2780. doi: 10.21037/jtd.2020.03.29.
7
Different efficacy in the non-small cell lung cancer patient with bilateral synchronous lesions treated with neoadjuvant gefitinib therapy: a case report.
J Thorac Dis. 2020 Apr;12(4):1582-1587. doi: 10.21037/jtd.2020.02.60.
8
Management of non-small cell lung cancer with resistance to epidermal growth factor receptor tyrosine kinase inhibitor: case discussion.
J Thorac Dis. 2020 Mar;12(3):159-164. doi: 10.21037/jtd.2020.01.65.
9
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
Br J Cancer. 2019 Oct;121(9):725-737. doi: 10.1038/s41416-019-0573-8. Epub 2019 Sep 30.
10
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
JAMA Oncol. 2019 Feb 1;5(2):173-180. doi: 10.1001/jamaoncol.2018.4305.
Zotero 插件